MedTrace Logo

A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

NCT05607563 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-02-08

No results posted yet for this study

Summary

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1009.

PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.

Conditions

  • Advanced Tumor

Interventions

DRUG

PM1009 injection

Participants receive PM1009 intravenously, every 2 weeks

Sponsors & Collaborators

  • Biotheus Inc.

    lead INDUSTRY

Principal Investigators

  • Ye Guo · Shanghai Orient Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-21
Primary Completion
2023-11-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05607563 on ClinicalTrials.gov